Transcatheter edge-to-edge repair (TEER) using the MitraClip device (Abbott) has been a significant advancement in the management of patients with severe mitral regurgitation (MR) who are considered high risk for conventional surgery1. Despite its widespread acceptance and growing application, the long-term benefits and patient selection criteria continue to be explored and debated within the clinical community234.
This single-centre retrospective study represents a comprehensive review of long-term outcomes with TEER using MitraClip, performed at the cardiac surgery department of San Raffaele University Hospital in Milan, Italy. It included a cohort of 150 consecutive patients with severe MR (≥3+) on echocardiographic assessment, treated between October 2008 and January 2013 for both primary (PMR) and secondary MR (SMR) (Supplementary Table 1), who were followed for 10 years after the procedure. Before the intervention, all patients were evaluated by a dedicated Heart Team.
EVEREST eligibility criteria5 were used as a reference, but patients outside them were also included. SMR patients were retrospectively assessed for COAPT eligibility6. All patients received first-generation MitraClip devices.
The cohort primarily consisted of males (78%),...
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
